Mobile Units take Therapies Development on-site
Global biotech Orgenesis is collaborating with Dong-a University Hospital (South Korea) and Cure Therapeutics to utilise Orgenesis’ Mobile Processing Units and Labs (OMPULs) for point-of-care development of cell and gene therapies and immunotherapies that meet regulatory and governmental approval standards to scale through to commercialisation. Process development and validation for the therapies will be completed at the Dong-a University.
“We are excited to expand our collaboration with Orgenesis by utilising their OMPULs onsite via a partnership with Dong-A University. The OMPULs will be placed onsite with the goal of accelerating development and commercialisation of our immunotherapies targeting cancers and infectious disease, while ensuring the highest
quality control standards and reducing overall manufacturing costs,” said David Kim, CEO of Cure Therapeutics.
“We are pleased to partner with Cure Therapeutics and Dong-a University Hospital to accelerate the development and market launch of breakthrough cell and gene therapies utilising our proprietary OMPUL system,” said Vered Caplan, CEO of Orgenesis. “This latest agreement is another step in our efforts to rollout OMPULs throughout our network of leading healthcare facilities and partner companies across the US, Europe, Asia and the Middle East.”
54656pr@reply-direct.com
Biotech adds CRISPR Technology for Models Development
Setsuro Tech, a Japanese biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, has signed a non-exclusive license for access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.
“The versatility and programmability of Cas9 has enabled the CRISPR/ Cas9 technology to become a revolutionary approach in biological research,” said Eric Rhodes, CEO of Dublin-based ERS Genomics. “We are pleased to support Setsuro Tech with this license agreement so that they are able to continue providing supportive tools and services for research activities.”
“Our technology enables us to provide researchers with genome-
edited models quickly and at relatively low cost,” commented Shinichiro Takezawa, CEO, Setsuro Tech, Tokushima. “The license from ERS expands our portfolio and having access to advanced technologies such as CRISPR/Cas9 will allow us to continue our high- quality offerings that combine CRISPR/Cas9 with our patent-pending technologies.”
Financial details of the agreement were not disclosed. More information online:
ilmt.co/PL/ZY3a
55104pr@reply-direct.com
Bio Square features at Thailand Lab International Exhibition 2021
more related partners from both government and private sectors, are collaborating to develop the trade show to serve the laboratory industry for the Southeast-Asia region.
Thailand Lab International organiser, VNU Asia Pacifi c, is ready to kick off the roadmap for the 2021 show promotion and confi rm the organisation of Southeast Asia’s leading exhibition and conference on Analytical Laboratory Technologies, Life Sciences, and Biotechnology Innovations - Thailand Lab International. The trade show will take place during 1-3 September 2021 at BITEC, Bangkok, together with Bio Asia Pacifi c, the new leading conference and exhibition platform for Biotechnology, Life Sciences and Smart Health in Asia Pacifi c. VNU Asia Pacifi c, together with Science and Technology Trade Association (STTA), Thailand Center of Excellence for Life Sciences (TCELS) and
Despite the challenges generated by the COVID-19 pandemic last year, Thailand Lab International still continued with the impressive success expected. The show, along with Bio Asia Pacifi c 2020, concluded with 109 exhibiting companies and 8,067 trade visitors. 65% of total trade visitors were physical and 35% were virtual. 47 physical conferences and 47 virtual conferences, plus 38 hybrid conferences (physical with live streamed content on YouTube live) were well attended. Over the course of three days 328 successful virtual meetings took place. The main attraction of the exhibition hall, ‘Bio Square’, featured a grand opening ceremony for the shows, including networking functions, start-up pitching, panel discussions and thoughtful leadership. Following its success last year, ‘Bio Square’ will once again appear as the show’s highlight, with a further developed format to increase interest. In 2021, the show will focus more on international attendees and also target local people who are interested in attending the show in-person or via virtual/online platforms, whether the travel restrictions remain or not. This will meet the organiser’s mission to create an interactive platform for trading, knowledge sharing, research and increased business opportunities.
More information online:
ilmt.co/PL/gq5k and
ilmt.co/PL/ZY0l 55026pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
